Digital ecosystem for customized patient care of the future

In order to guarantee the best possible therapy for patients, medical products must be constantly improved. Therefore, a nationwide project was launched in 2020. The project KIKS aims to develop a digital ecosystem for medical data – AIQNET.

In future, AIQNET aims to make medical data more exchangeable and usable for research, diagnosis and treatment. Artificial intelligence will be used to automate data analysis and structuring. Dr. Ina Wüstefeld, Vice President Regulatory & Medical Scientific Affairs at Aesculap AG, explains in the following interview which advantages the new global ecosystem might bring for patients, doctors and manufacturers.

Why did a global player like Aesculap decide to support a digital ecosystem like AIQNET? What are the advantages? 

Dr. Ina Wüstefeld: Artificial intelligence is a key technology of high strategic importance. Especially for Aesculap, an innovative medical technology company, it is important to use this technology in areas such as product safety, clinical benefit, production, research and development and to continuously advance it. Hereby, the project plays a significant role in order to focus more on  customers and patients. AIQNET offers not only direct economic advantages like more efficient and faster data collection, but also long-term partnerships with customers and service providers.

What expectations do you have of AIQNET and the cooperation with other partners?

Dr. Ina Wüstefeld: The ecosystem must be able to collect, analyze and process data in the fields of diagnosis, therapy, clinical research, innovation and product safety. The technical realization offers state-of-the-art algorithms and gives us a better understanding of various clinical factors in therapy. At the same time, it provides a safe legal framework – e.g. protection of personal data – and a technically safe infrastructure, namely cybersecurity.

An "ecosystem" lives from its stakeholders – the current and future project partners. Our expectation is therefore an effective collaboration to provide patients and users with safe and efficient medical products.

How does AIQNET benefit the patient?

Dr. Ina Wüstefeld: We expect that the new ecosystem will allow individualized preparation of a patient for treatment. Individualization of treatment is also a conceivable option. AIQNET provides a link between a wide variety of data sources which were created at various points in the product life cycle and in interaction with patients and users. This allows insight into the effect of biological and technical parameters on the treatment outcome. If, for example, a patient is suffering from an identified risk factor prior to the medical intervention, the physician can take preparatory action instead of having to react to a complication. If, for example, weaknesses in products become frequently apparent, it results in targeted product development. Consequently, all these factors have a positive effect on patient care.

Which aspects of the project are particularly important to you?

Dr. Ina Wüstefeld: Our focus lies on the patient, the doctor or the user. The "new" technologies lead us to an unprecedented understanding of a best possible, result-oriented treatment and future-oriented partnership with all parties involved. B. Braun Aesculap, with its guiding principle of Sharing Expertise, aims to be both a pioneer and a role model in this field.

It enables manufacturers to objectively measure and compare the performance and safety of medical products in accordance with European legislation. The open platform offers partners the opportunity to develop their own healthcare applications and make them available to different users, including patients.

Source: https://www.biolago.org/…

Über AIQNET

AIQNET is a digital ecosystem that enables the use of medical data across sectors and in compliance with data protection regulations. The entire project is coordinated by BioRegio STERN Management GmbH, Stuttgart. Initiator and consortium leader is RAYLYTIC GmbH, based in Leipzig.
The consortium of 16 established medical technology and healthcare companies won the German government’s Al petition in 2019 under the project acronym "KIKS". The project is funded by the Federal Ministry for Economic Affairs and Energy. Since January 2020, the project partners have been developing the technical infrastructure and its applications. The focus is on structuring data using artificial intelligence and creating a legally secure framework. In the future, for example, the performance and safety of medical devices can be measured objectively and largely automatically. Administrative tasks of healthcare, e.g. documentation, can be handled by relevant applications. A special feature of the project is the close cooperation between industry, research and healthcare.

By providing access to technical and scientific data with great depth, the ecosystem offers future partners the opportunity to develop their own health applications at low cost and to benefit from the legally secure, validated framework of AIQNET.

Firmenkontakt und Herausgeber der Meldung:

AIQNET
Petersstr. 32-34
04109 Leipzig
Telefon: +49 711 870354 23
http://www.aiqnet.eu

Ansprechpartner:
Eva Botzenhart-Eggstein
BioLago e.V.
Telefon: +49 7531 9215 253
E-Mail: eva.botzenhart@biolago.org
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel